Lunatus Partners with Nanthealth to Bring Gps Cancer™ to Oncologists and Patients in The Middle East
In December 2016, Lunatus entered into an exclusive reseller agreement with NantHealth, a leading next-generation, evidence-based, personalized healthcare company, for GPS Cancer Advanced Molecular Analysis. The molecular tests will help guide the decisions made by oncologists in the Middle East regarding a patient’s treatment strategy, including choice of standard chemotherapy....
